PARP1 and myeloid sarcoma: Remyelination failure has been proposed as one of the major reasons for MS disease progression.[174] Consistently, promoting OL regeneration and remyelination has been shown to prevent axonal loss and improve functional recovery in EAE mouse model of MS.[2a] PARP1's enzymatic activity has been reported to be dysregulated in oligodendroglial lineage cells in MS and animal models.[15, 16] Hence, the future translation of PARP1 inhibition into MS therapies must consider the potential role of PARP1 in OL damage and regeneration.